# Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

> **NCT00667329** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** 2CdA
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00667329
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07-09
- **Primary completion:** 2022-02-10
- **Final completion:** 2022-02-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667329, "Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00667329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*